Sleep disturbance is one of the most common yet underrecognized complications of chronic kidney disease (CKD), affecting an estimated 50–80% of patients with advanced kidney disease and nearly all patients on dialysis. Poor sleep in CKD is not simply a side effect of stress or anxiety — it reflects a complex interaction of physiological changes driven by CKD itself: uremic toxin accumulation, mineral imbalances, hormonal disruption, restless leg syndrome, sleep apnea, nocturnal symptoms, and the cumulative burden of multiple concurrent medical conditions. The consequences of chronic poor sleep extend well beyond daytime fatigue: poor sleep accelerates cardiovascular disease, worsens glucose control and blood pressure, impairs immune function, contributes to depression and cognitive decline, and — in some studies — is independently associated with faster CKD progression. Despite this, sleep problems are frequently not addressed at CKD clinic visits, partly because patients normalize poor sleep as “just part of having kidney disease” and partly because the clinical tools for systematic sleep assessment are not always incorporated into nephrology practice. This article covers the major sleep disorders that affect CKD patients, explains why each develops and how it is identified and treated, and gives patients practical guidance for improving sleep quality and raising sleep concerns with their care team. For patients who want to understand the full psychological and cognitive impact of CKD, the companion article on kidney disease and mental health addresses depression, anxiety, and cognitive decline in CKD in detail.
Why Kidney Disease Disrupts Sleep: The Physiological Mechanisms
Sleep disruption in CKD is not a single problem with a single cause — it reflects multiple physiological mechanisms operating simultaneously, each contributing to difficulty falling asleep, difficulty staying asleep, non-restorative sleep, or specific movement disorders during sleep. Understanding these mechanisms helps patients recognize that their sleep problems are medical in nature and can often be treated, rather than inevitable consequences of kidney disease to simply endure. Uremic toxin accumulation: as kidney function declines, uremic toxins — the metabolic byproducts that healthy kidneys would excrete — accumulate in the bloodstream and affect virtually every organ system, including the brain. Uremic toxins disrupt normal sleep-wake regulation by altering the production and activity of neurotransmitters involved in sleep, including serotonin (a precursor to melatonin), GABA, and adenosine. This produces a pattern sometimes called “uremic insomnia” — difficulty achieving restful sleep despite physical fatigue, associated with lighter sleep stages and reduced slow-wave (deep) sleep. Hormonal disruption: melatonin, the primary hormone that signals nighttime to the body and induces sleep, is significantly dysregulated in CKD. Studies consistently show reduced nocturnal melatonin levels in dialysis patients, with loss of the normal day-night melatonin rhythm that characterizes healthy sleep-wake cycles. This circadian rhythm disruption makes it harder to fall asleep at night and contributes to daytime sleepiness. Erythropoietin deficiency (the anemia-causing hormone deficiency in CKD, covered in the companion article on kidney disease and anemia) also disrupts sleep through poorly understood mechanisms, and treatment of anemia in CKD is associated with improved sleep quality in some studies. Mineral and acid-base imbalances: uremic restless leg syndrome (one of the most prevalent CKD sleep disorders, discussed below) is directly linked to iron deficiency, uremia, and neural changes in dopaminergic pathways — all of which are influenced by kidney disease and dialysis adequacy. Metabolic acidosis and hyperphosphatemia contribute to muscle cramps and neurological symptoms that can disrupt sleep. Obstructive sleep apnea: CKD independently increases risk for obstructive sleep apnea, partly through fluid redistribution — fluid retained during the day in the legs shifts into the neck and upper airway during recumbent sleep, increasing upper airway collapse risk. This mechanism is particularly relevant in dialysis patients, who accumulate substantial fluid between dialysis sessions. Psychosocial burden: the psychological impact of a life-altering chronic illness — dealing with multiple medications, dietary restrictions, dialysis schedules, uncertainty about transplant, and fear of progression — contributes substantially to anxiety-related sleep disruption, which is a separate problem from the physiological mechanisms above and requires its own management strategies. The NIDDK overview of CKD complications is at the NIDDK CKD overview page.
Restless Leg Syndrome in CKD: Prevalence, Mechanism, and Treatment
Restless leg syndrome (RLS) — also called Willis-Ekbom disease — is a neurological sensorimotor disorder characterized by an uncomfortable, irresistible urge to move the legs, typically in the evening or at rest, that is relieved by movement. It is one of the most prevalent and treatable sleep disorders in CKD. RLS affects approximately 20–30% of CKD patients and up to 50% of patients on hemodialysis — rates 10–20 times higher than in the general population. Symptoms of RLS: the hallmark is an uncomfortable sensation in the legs (described variously as crawling, creeping, tingling, burning, or a deep ache) that is worse at rest (particularly in the evening and night) and is relieved by moving, stretching, or walking. These sensations typically force patients to get up and pace at bedtime, making sleep onset extremely difficult. Periodic limb movements during sleep (PLMS) — involuntary jerking of the legs during sleep, separate from the waking RLS sensations but often co-occurring — further disrupt sleep architecture by causing brief arousals that fragment sleep without full awakening. Why CKD causes RLS: the exact mechanism is incompletely understood, but iron deficiency in the brain’s dopaminergic pathways appears central to RLS pathophysiology. In CKD, iron deficiency is extremely common (contributing to both anemia and RLS); uremic toxins affect dopaminergic neurotransmission; and dialysis itself introduces additional stressors on these pathways. Dialysis adequacy is inversely correlated with RLS severity — better uremic toxin clearance improves RLS symptoms, suggesting that uremia itself drives part of the syndrome. Diagnosing RLS in CKD: RLS is a clinical diagnosis based on symptom history — the four key features are (1) an urge to move the legs, (2) symptoms worse at rest, (3) symptoms partially or fully relieved by movement, and (4) symptoms worse in the evening or night. Patients often do not spontaneously report RLS at nephrology visits because they assume it is just part of their kidney disease, do not know it has a name, or do not connect it to their sleep problems. Nephrologists should routinely screen for RLS by asking specifically about leg discomfort at rest or at bedtime. Treatment of RLS in CKD: first-line management focuses on addressing contributing factors: correcting iron deficiency (intravenous iron is often more effective than oral iron in CKD patients, and is routinely given in dialysis patients), optimizing dialysis adequacy (increasing dialysis dose or frequency may reduce uremic RLS), and reviewing medications that worsen RLS (antihistamines, antinausea medications such as metoclopramide, antidepressants, and antipsychotics can all worsen RLS). When these measures are insufficient, pharmacological treatment includes dopamine agonists (ropinirole, pramipexole) and alpha-2-delta calcium channel ligands (gabapentin, pregabalin) — with the important caveat that all of these medications require kidney-adjusted dosing in CKD, and gabapentin and pregabalin in particular accumulate significantly in advanced CKD and dialysis. The choice of agent and dose in CKD should be guided by a nephrologist or neurologist familiar with RLS management in renal failure. The KDIGO guidelines on anemia and related complications are at the KDIGO anemia guidelines page.
Obstructive Sleep Apnea in CKD: Mechanisms, Cardiovascular Consequences, and Treatment
Obstructive sleep apnea (OSA) — the repeated collapse of the upper airway during sleep, causing cessation of breathing (apnea) or reduced airflow (hypopnea) — is substantially more prevalent in CKD patients than in the general population. Estimated OSA prevalence in dialysis patients ranges from 40–70% in systematic studies — far higher than the 10–15% prevalence in the general adult population — yet the majority of cases are undiagnosed and untreated because sleep symptoms are not systematically screened in nephrology practice. Why CKD promotes sleep apnea: the primary CKD-specific mechanism is nocturnal fluid redistribution. During the day, CKD patients (particularly those on dialysis who accumulate fluid between sessions) retain fluid in the legs due to elevated venous pressure and reduced lymphatic drainage. When the patient lies down, this leg fluid redistributes into the neck and peripharyngeal tissues, increasing the volume of soft tissue around the upper airway and reducing its diameter — predisposing to collapse during inspiration. The amount of fluid redistribution correlates with interdialytic weight gain (the amount of fluid accumulated between dialysis sessions), and studies in hemodialysis patients have shown that more fluid removal during dialysis is associated with lower apnea-hypopnea index (AHI). Other contributing factors include altered central respiratory drive from uremia, upper airway muscle dysfunction from uremic neuropathy, and obesity — which is itself associated with both CKD and OSA. Cardiovascular consequences of untreated OSA in CKD: untreated OSA causes repeated hypoxemia, sympathetic nervous system activation, and blood pressure surges during each apnea event. In a general population, OSA significantly increases risk of hypertension, atrial fibrillation, heart failure, and stroke. In CKD patients who already have dramatically elevated cardiovascular risk from kidney disease itself (discussed in the article on kidney disease and heart health), the additional cardiovascular burden of untreated OSA is clinically meaningful. Nocturnal hypertension from OSA is particularly relevant in CKD because blood pressure during sleep is one of the strongest predictors of end-organ damage and kidney disease progression. Diagnosing OSA in CKD: the STOP-BANG questionnaire (Snoring, Tiredness, Observed apnea, Blood Pressure, BMI, Age, Neck circumference, Gender) is a validated screening tool that CKD patients can complete themselves. A score of 3 or higher indicates elevated OSA risk and warrants referral for formal sleep testing. Home sleep apnea testing (HSAT) is appropriate for most CKD patients with uncomplicated suspected OSA; in-lab polysomnography is preferred when central sleep apnea, severe hypoxemia, or other complicating factors are suspected. Treatment of OSA in CKD: continuous positive airway pressure (CPAP) is first-line treatment for moderate-to-severe OSA and is effective in CKD patients. CPAP improves sleep quality, reduces daytime sleepiness, lowers nocturnal blood pressure, and reduces cardiovascular event risk in the general OSA population — benefits that are at least as relevant for CKD patients. Fluid management strategies that reduce interdialytic fluid accumulation — dietary sodium restriction, increased dialysis frequency or duration, or intensified ultrafiltration — can independently reduce OSA severity in dialysis patients by reducing the nocturnal fluid redistribution mechanism. The NKF patient resource on CKD and sleep is at the NKF sleep disorders and CKD page.
Improving Sleep in CKD: Practical Strategies and Raising Sleep Concerns With Your Care Team
Beyond addressing specific disorders like RLS and OSA, CKD patients can take active steps to improve sleep quality through behavioral strategies, optimizing their dialysis schedule, and working with their care team to identify and treat contributing medical factors. Sleep hygiene in CKD: the standard sleep hygiene principles apply to CKD patients, with CKD-specific modifications. Maintaining a consistent sleep schedule (same bedtime and wake time daily, including dialysis days) reinforces circadian rhythm. Keeping the bedroom cool, dark, and quiet reduces arousal barriers. Avoiding caffeine after noon is especially important in CKD patients who have slower caffeine metabolism due to impaired renal excretion. Avoiding large fluid intake in the hours before bed reduces nocturnal urination frequency — particularly relevant in CKD patients with residual kidney function who may need to void frequently during the night. Avoiding napping during the day (particularly for dialysis patients who tend to sleep post-session) helps maintain nighttime sleep pressure. Dialysis timing and sleep: hemodialysis schedule can significantly affect sleep. Evening dialysis sessions (late afternoon through evening) are associated with worse subsequent sleep quality because of the physiological stress, electrolyte shifts, and stimulant effects of the dialysis session itself. Where possible, dialysis sessions earlier in the day may improve nighttime sleep. Patients on home hemodialysis who do nocturnal dialysis (sleeping during treatment) report high satisfaction with this modality and significant improvement in sleep and quality of life, in part because frequent nocturnal dialysis provides superior uremic toxin clearance and better mineral balance. Melatonin supplementation: several small studies have found that low-dose melatonin (0.5–5 mg at bedtime) modestly improves sleep latency and quality in CKD and dialysis patients, consistent with the known melatonin circadian disruption in this population. Melatonin is generally safe in CKD, does not require kidney elimination, and is available over the counter. Patients should discuss melatonin use with their nephrologist before starting, particularly if they are taking other CNS-active medications. Raising sleep concerns at nephrology visits: because sleep is not always systematically asked about in nephrology practice, patients who are struggling with sleep should proactively raise it — describing the type of sleep problem (difficulty falling asleep, staying asleep, non-restorative sleep, or specific RLS or snoring symptoms), its frequency and severity, and how it affects daytime function. Useful questions to ask include: “Could my sleep problem be related to my kidney disease or medications?” and “Should I be screened for restless leg syndrome or sleep apnea?” The connection between poor sleep and worsened kidney disease outcomes — through blood pressure, inflammation, and metabolic stress — means that sleep management is a legitimate clinical priority in CKD care, not a secondary concern. For patients managing kidney disease across its full spectrum of complications, the article on kidney disease and long-term monitoring covers how to track disease progression and symptom burden, and the kidney failure treatment options article discusses how different dialysis modalities affect quality of life including sleep. The StatPearls reference on sleep disorders in kidney disease is at the StatPearls sleep disorders resource.
Sources: NIDDK CKD Overview · KDIGO Anemia Guidelines · National Kidney Foundation · StatPearls: Sleep Disorders in CKD
Nocturnal Urination, Dialysis-Related Sleep Disruption, and Daytime Sleepiness
Beyond RLS and OSA, CKD patients face several additional sleep-disrupting factors that are directly related to their kidney disease and its treatment. Nocturia in CKD: nocturia — the need to urinate one or more times per night — is nearly universal in CKD patients who still have residual kidney function. Healthy kidneys concentrate urine at night, allowing uninterrupted sleep. As CKD progresses, concentrating ability is lost early in the disease course, and the kidneys produce dilute, high-volume urine around the clock. The result is that CKD patients may need to urinate 2–4 times per night even with careful fluid management, fragmenting sleep and making it impossible to achieve the prolonged unbroken sleep cycles needed for restorative deep sleep and REM sleep. Management strategies for nocturia in CKD include: avoiding fluid intake in the 2–3 hours before bed (allowing the bladder to empty before sleep and reducing urine accumulation during the first sleep cycles); timing diuretic medications for the morning rather than evening where possible; and elevating the legs in the afternoon to reduce peripheral fluid accumulation before bedtime (less fluid in the legs means less fluid mobilized into the circulation during recumbent sleep, reducing renal perfusion and urine production at night). Nocturnal polyuria can also be a sign of poorly controlled diabetes or bladder dysfunction, so persistent nocturia should be discussed with the care team to distinguish CKD-related from other treatable causes. Post-dialysis fatigue and its relationship to sleep: hemodialysis is a physiologically stressful procedure. Most patients experience significant fatigue for hours after their dialysis session — the so-called post-dialysis fatigue syndrome — which can last 6–12 hours and is one of the most burdensome symptoms reported by dialysis patients. Post-dialysis fatigue appears related to rapid fluid and electrolyte shifts, cytokine activation, reduced cerebral perfusion during ultrafiltration, and the cumulative stress of repeated sessions three times weekly. The timing of dialysis sessions relative to sleep therefore matters: patients who dialyze in the afternoon or evening often feel too fatigued to be normally active but not fatigued enough to sleep soundly at night, creating a dissociation between physical exhaustion and the specific neurological state needed for restorative sleep. For patients who have flexibility in dialysis scheduling, morning or early afternoon sessions may better preserve nighttime sleep quality. Peritoneal dialysis patients (who perform dialysis continuously or during sleep) generally report better sleep quality than in-center hemodialysis patients, and this is one of the quality-of-life advantages that can factor into dialysis modality choice — discussed further in the article on kidney failure treatment options. Daytime sleepiness in CKD: excessive daytime sleepiness (EDS) is a highly prevalent complaint in CKD patients and has multiple potential causes: nighttime sleep fragmentation from any of the above mechanisms, uremic neurotoxicity, anemia-related fatigue (covered in the article on kidney disease and anemia), depression (covered in the article on kidney disease and mental health), and the sedating effects of medications commonly prescribed in CKD (gabapentin, antihypertensives, sedatives). Distinguishing primary daytime sleepiness from tiredness due to anemia or depression requires clinical assessment — patients should bring up EDS at clinic visits and describe its severity, when it occurs, and any relationship to dialysis sessions or nighttime sleep quality. The Epworth Sleepiness Scale — a validated self-administered questionnaire asking about likelihood of dozing in various situations — can be completed before a clinic visit to provide objective data. A score above 10 typically warrants investigation for sleep disorders. Medications that affect sleep in CKD: several medications commonly prescribed in CKD significantly affect sleep quality. Corticosteroids (used in some glomerular diseases) cause insomnia. Beta-blockers (used in CKD patients with hypertension and cardiovascular disease) can cause nightmares, vivid dreams, and sleep disturbance — a less lipophilic beta-blocker (atenolol, bisoprolol) may cause less sleep disruption than lipophilic agents (propranolol, metoprolol). Loop diuretics (furosemide, torsemide) taken in the evening cause nocturnal urination. Gabapentin accumulates in renal failure and causes excessive sedation and daytime grogginess — doses need careful downward adjustment in CKD. Patients should review their medication list with their nephrologist specifically from the perspective of sleep impact, particularly after any medication change that correlates with worsening sleep. The NIDDK patient guidance on managing CKD symptoms is at the NIDDK CKD symptom management page.
Sleep is not a peripheral concern in CKD management — it is a core determinant of quality of life, cardiovascular health, blood pressure control, and mental wellbeing. Patients who actively address their sleep problems — whether by pursuing diagnosis and treatment for RLS or OSA, optimizing their dialysis schedule, improving sleep hygiene, or discussing medication effects with their nephrologist — consistently report meaningful improvements in daytime energy, mood, and overall functioning. The overlap between sleep and the broader spectrum of CKD complications means that improving sleep often has ripple effects on blood pressure control, anemia management, and psychological wellbeing, making it one of the highest-leverage quality-of-life interventions available to CKD patients who are struggling with multiple concurrent burdens. Sleep problems in CKD are medical conditions deserving of systematic clinical attention — not a background noise of suffering to be accepted without inquiry or treatment. The article on kidney disease and high blood pressure covers the relationship between nocturnal blood pressure, sleep apnea, and kidney disease progression in detail.
I’ve been on hemodialysis for three years and I have severe restless leg syndrome — it’s honestly one of the worst parts of my situation. I didn’t know it was this common in dialysis patients or that iron was a factor. My care team has been giving me IV iron for my anemia but never connected it to my RLS. Going to specifically ask whether my iron levels could be better optimized for the RLS. Thank you for putting all this together.
Patricia, you’ve identified something that often falls through the cracks — iron optimization in dialysis is typically guided by anemia management targets (hemoglobin, ferritin, transferrin saturation), but RLS responds to iron repletion through a separate mechanism involving brain dopaminergic pathways. Some dialysis patients with RLS benefit from higher iron targets than what is used for anemia management alone. It’s worth asking your nephrologist specifically about RLS and iron, and whether your current iron protocol is taking it into account. A neurology referral for RLS management is also reasonable if symptoms are significantly affecting quality of life.
The section about fluid redistribution causing sleep apnea was something I had never heard before. I was diagnosed with sleep apnea before my CKD diagnosis and always thought they were unrelated. Now I understand the connection and it makes me more motivated to stick to my fluid and sodium restrictions — if I reduce my interdialytic weight gain, it may actually improve my sleep apnea severity. That’s a much more compelling reason to stay on track than just blood pressure.